Literature DB >> 17005746

Characteristics of Staphylococcus aureus strains isolated in Poland in 1996 to 2004 that were deficient in species-specific proteins.

Agnieszka Luczak-Kadlubowska1, Jolanta Krzyszton-Russjan, Waleria Hryniewicz.   

Abstract

One hundred seventy Staphylococcus aureus isolates, collected in 1996 to 2004, were reidentified by phenotypic and genotypic methods. One hundred ten of these (65%) were confirmed, as previously denoted, to be clumping factor (CF)- or free coagulase-deficient S. aureus, based on their phenotype. Based on the CF or coagulase production, three groups of phenotypically deficient S. aureus isolates were distinguished. Group 1 encompassed CF-positive and coagulase-deficient isolates, group 2 consisted of CF-deficient and coagulase-positive isolates, and group 3 included isolates that were CF positive, had delayed coagulase activity, and were deficient in other species-specific features. All investigated strains harbored the clfA, clfB, coa, spa, and nuc genes, but the presence of their products was not detected by the phenotypic methods. Glycopeptide susceptibility testing showed that 26 isolates (23.6%) were hetero-glycopeptide-intermediate S. aureus(hGISA) or hetero-teicoplanin-intermediate S. aureus (hTISA), based on the population analysis profile. The relatedness of the isolates was evaluated by multiple-locus variable number of tandem repeats analysis, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing. The phenotypically deficient S. aureus isolates were classified into PFGE types B (ST239-III) and D (ST246-IA) and were related to the common clones, Hungarian and Iberian, respectively, which have been widely disseminated in Poland and globally. The simultaneous occurrence of hGISA/hTISA and the CF-deficient phenotypes was found for 62.1% of isolates belonging to group 2. The majority of these isolates were assigned to the Iberian clone (PFGE type D; ST247-IA). An association between the defect in coagulase and that in thermonuclease production was observed, which concerned 59.2% of isolates of group 1. The majority of these isolates belonged to the Hungarian clone (PFGE type B; ST239-III).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005746      PMCID: PMC1698328          DOI: 10.1128/JCM.01164-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  50 in total

1.  Wide geographic distribution of a unique methicillin-resistant Staphylococcus aureus clone in Hungarian hospitals.

Authors:  Herminia de Lencastre; Elena P. Severina; Hedda Milch; Marianne Konkoly Thege; Alexander Tomasz
Journal:  Clin Microbiol Infect       Date:  1997-06       Impact factor: 8.067

Review 2.  Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus.

Authors:  Duarte C Oliveira; Alexander Tomasz; Hermínia de Lencastre
Journal:  Lancet Infect Dis       Date:  2002-03       Impact factor: 25.071

3.  Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.

Authors:  Mandy Wootton; Peter M Bennett; Alasdair P MacGowan; Timothy R Walsh
Journal:  J Antimicrob Chemother       Date:  2005-09-12       Impact factor: 5.790

4.  A Shared noncapsular antigen is responsible for false-positive reactions by Staphylococcus epidermidis in commercial agglutination tests for Staphylococcus aureus.

Authors:  J E Blake; M A Metcalfe
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Comparison of multiple-locus variable-number tandem-repeat analysis with pulsed-field gel electrophoresis, spa typing, and multilocus sequence typing for clonal characterization of Staphylococcus aureus isolates.

Authors:  Natalia Malachowa; Artur Sabat; Marek Gniadkowski; Jolanta Krzyszton-Russjan; Joanna Empel; Jacek Miedzobrodzki; Klaudia Kosowska-Shick; Peter C Appelbaum; Waleria Hryniewicz
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  Comparison of five agglutination tests for identification of Staphylococcus aureus.

Authors:  M Wilkerson; S McAllister; J M Miller; B J Heiter; P P Bourbeau
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 7.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

8.  Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis.

Authors:  D C Schwartz; C R Cantor
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

9.  Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus.

Authors:  D Ní Eidhin; S Perkins; P Francois; P Vaudaux; M Höök; T J Foster
Journal:  Mol Microbiol       Date:  1998-10       Impact factor: 3.501

10.  Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesins.

Authors:  P E Vaudaux; V Monzillo; P Francois; D P Lew; T J Foster; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

View more
  2 in total

1.  Countrywide molecular survey of methicillin-resistant Staphylococcus aureus strains in Poland.

Authors:  Agnieszka Łuczak-Kadłubowska; Agnieszka Sulikowska; Joanna Empel; Anna Piasecka; Monika Orczykowska; Aleksandra Kozinska; Waleria Hryniewicz
Journal:  J Clin Microbiol       Date:  2008-07-09       Impact factor: 5.948

2.  Occurrence, distribution and pattern analysis of methicillin resistant (MRSA) and methicillin sensitive (MSSA) Staphylococcus aureus on fomites in public facilities.

Authors:  Ziad W Jaradat; Maysoon Khwaileh; Waseem Al Mousa; Qutaiba O Ababneh; Anas Al Nabulsi
Journal:  Pathog Glob Health       Date:  2021-08-02       Impact factor: 3.735

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.